Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin tolerability and polymorphism study in metastatic breast cancer
2013-004600-19Phase 4Active
- Sponsor
- Azienda Ospedaliera Fatebenefratelli e Oftalmico
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eribulin in breast cancer, sponsored by Azienda Ospedaliera Fatebenefratelli e Oftalmico. Primary endpoint: Incidence, time of onset, severity and duration of adverse events during eribulin treatment. Started Dec 2013; status: active.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-004600-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004600-19.